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with 1-month dual antiplatelet therapy (DAPT) has shown superior safety and efficacy outcomes compared with bare-metal
stents among patients with high-bleeding risk (HBR) treated with 1-month DAPT. The safety and efficacy of the newer-generation
durable-polymer DES Resolute Onyx compared with polymer-free DES among HBR patients treated with 1-month DAPT is
unknown.
Trial Design The Onyx ONE global randomized trial is an international, prospective, randomized, blinded, controlled
study enrolling HBR patients undergoing percutaneous coronary intervention. The trial will randomize up to 2,000 patients in a
1:1 fashion to receive either the durable-polymer Resolute Onyx DES or the polymer-free Biosensors BioFreedom DES. After
index procedure, patients in both arms will be treated with 1 month of DAPT (aspirin and oral P2Y12 inhibitor), followed by
single antiplatelet therapy thereafter. The primary end point is the composite end point of cardiac death, myocardial infarction,
or stent thrombosis at 1-year follow-up. The powered secondary end point is target lesion failure (defined as the composite of
cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization) at 1 year. Patient follow-
up is planned for 1, 2, and 6 months and 1 and 2 years after the procedure.
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https://doi.org/10.1016/j.ahj.2019.04.017The duration of dual antiplatelet therapy (DAPT) after
coronary artery stenting has been a topic of debate for
several decades. Although 1-month DAPT in patients
receiving bare-metal stent (BMS) treatment has been
considered safe (1,2), the optimal duration of DAPT after
drug-eluting stent (DES) implantation is unclear. Con-
cerns with first-generation DES of very late-stent throm-
bosis (ST) led to recommendations for prolonged DAPT
of ≥12-months (3), despite the lack of clinical evidence
supporting this approach. Furthermore, newer-
generation devices with thinner struts, improved durable
polymer biocompatibility, bioabsorbable polymers, or
polymer-free DES have significantly reduced major
adverse cardiac events (MACEs) such as ST and conse-
quently the need for an extended duration of DAPT.
Indeed, several randomized clinical trials of newer-
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Volume 214generation DES did not find an increased risk of stent
thrombosis with 3 to 6 months DAPT (4-7). The
American College of Cardiology/American Heart Associ-
ation and European Society of Cardiology guidelines
recommend a minimum of 6 and 12 months DAPT for
newer-generation DES in non–high-bleeding risk (HBR)
patients with stable coronary artery disease and acute
coronary syndromes, respectively (8,9).
Although longer DAPT regimens may reduce throm-
botic events after stenting and non–stent-related cardio-
vascular events, prolonged DAPT usage is associated with
increased bleeding risk (10). Therefore, HBR patients
undergoing percutaneous coronary intervention (PCI)
are sometimes treated with BMS in combination with
1 month of DAPT, although this is no longer routinely
recommended (9). Shorter DAPT duration (1 month of
DAPT with a class IIB, level of evidence C recommenda-
tion; 3 months of DAPT with a class IIA, level of evidence
B recommendation) may be appropriate for certain HBR
patients receiving DES (9); these recommendations were
based on recent randomized clinical trials that investigat-
ed the impact of shortened DAPT on selected HBR
patients after stent implantation, including the Zotaroli-
mus-Eluting Endeavor Sprint Stent in Uncertain DES
Candidates (ZEUS) (11) and Prospective Randomized
Comparison of the BioFreedom Biolimus A9 Drug-Coated
Stent versus the Gazelle Bare-Metal Stent in Patients at
High Bleeding Risk (LEADERS FREE) trials (12).
ZEUS randomized patients designated as HBR or high
thrombotic risk to any BMS or the Endeavor DES
(Medtronic, Santa Rosa, CA) (13). HBR and stable high-
thrombotic-risk patients were prescribed 1-month DAPT
after the procedure. The risk of MACEs at 1 year was
significantly lower in the DES group (11). The LEADERS
FREE trial randomly assigned HBR patients to the
polymer-free BioFreedom (Biosensors Europe, Morges,
Switzerland) DES platform or BMS in conjunction with 1-
month DAPT (14). Polymer-free DES was superior to BMS
for the primary composite end point of cardiac death,
myocardial infarction (MI), or ST at 1 year (12). A similar
treatment effect with polymer-free DES was observed in
various subgroups of the LEADERS FREE trial, including
patients older than 75 years (15), with diabetes (16) and
with acute coronary syndrome (17), and those requiring
chronic oral anticoagulation (18). A third study of
relevance is the SENIOR trial, which found that 1 and
6 months of DAPT was safe in elderly patients treated
with the Synergy stent (Boston Scientific, Marlborough,
MA), which elutes everolimus from a bioabsorbable
polymer (19).
Both European Society of Cardiology and American
College of Cardiology guidelines acknowledge that there
is limited clinical evidence evaluating the optimal
duration of DAPT in HBR patients after stent implanta-
tion. In particular, there are no data comparing the safety
and efficacy of polymer-free DES with newer-generationdurable-polymer DES among HBR patients requiring 1-
month DAPT. The thin-strutted Resolute Onyx (Medtro-
nic) DES is the latest iteration of the Resolute DES
platform and has been commercially available since 2014.
The Resolute Onyx shares the identical polymer and drug
with previous Resolute stent platforms (20,21), but is
formulated from a cobalt alloy wire with a platinum
iridium core, enabling thinner struts while maintaining
radial strength and radio-opacity. The safety and efficacy
of the Resolute DES product family has been demonstrat-
ed in more than 17,000 patients enrolled in the
RESOLUTE Global Clinical Program, including more
than 10 clinical studies and registries. Specifically, in an
analysis of 7,618 patients, the Resolute stent demonstrat-
ed a low rate of cardiac events and a 1.2% stent
thrombosis rate through 5 years of follow-up (22).
Furthermore, in a post-hoc analysis of 4,896 patients
from the RESOLUTE Global Clinical Program, DAPT
interruption between 1 and 12 months after Resolute
stent implantation was associated with low rates of stent
thrombosis and adverse cardiac outcomes, with the
majority of events occurring within the first 30 days (23).
Considering the favorable safety and efficacy profile of
the Resolute family of DES, it is conceivable that Resolute
Onyx may be safe and effective in HBR patients requiring
shorter DAPT. Furthermore, Resolute Onyx demonstrat-
ed high rates of Optical Coherence Tomography-assessed
coverage rate 30 days after implantation, with 92.3% of
the total lumen surface area fully covered (24).
In this context, the Onyx ONE global randomized trial
was designed to compare the clinical safety and
effectiveness of the Resolute Onyx DES with the
BioFreedom DES in patients at HBR or medically
unsuitable for longer than 1 month of DAPT.Methods
Trial design
OnyxONE is a prospective, single-blinded trial planned
to randomize up to 2,000 patients at 86 clinical sites in
Asia-Pacific and Europe. The trial was designed by the
sponsor (Medtronic) in conjunction with the steering
committee (listed in the Appendix) and the US Food
and Drug Administration. The trial was funded by
Medtronic.
The trial design is illustrated in Figure 1. Patients
enrolled are eligible for PCI and must meet predefined
HBR criteria similar to those in the LEADERS FREE trial
(14). All inclusion and exclusion criteria are listed in
Table I. Key exclusion criteria include active bleeding at
the time of inclusion, cardiogenic shock, PCI during the
previous 6 months for a nontarget lesion, planned PCI
more than 1 month after index procedure, or any
planned surgery/procedure necessitating discontinuation
of DAPT within 1 month after the index procedure.
Figure 1
Trial design.
Table I. Inclusion and exclusion criteria for Onyx ONE global
study.
clusion criteria
• Acceptable candidate for treatment with a DES
• Provide written informed consent
• Meet one of the following criteria for being HBR and/or are
candidates for 1-mo DAPT:
o Adjunctive oral anticoagulation treatment planned to continue
after PCI
o Age ≥75 y
o Baseline Hgb b11 g/dL (or anemia requiring transfusion during the
4 wk before randomization)
o Any prior documented intracerebral bleed
o Any documented stroke in the last 12 mo
o Hospital admission for bleeding during the prior 12 mo
o Nonskin cancer diagnosed or treated ≤3 y
o Planned daily NSAID (other than aspirin) or steroids for ≥30 d
after PCI
o Planned surgery that would require interruption of DAPT (within
the next 12 mo)
o Renal failure defined as: creatinine clearance b40 mL/mi
o Thrombocytopenia (PLT b100,000/mm3)
o Severe chronic liver disease defined as variceal hemorrhage,
ascites, hepatic encephalopathy, or jaundice
o Expected noncompliance to prolonged DAPT for other medical
reasonsExclusion criteria
• Pregnant and breastfeeding women
• Patients requiring a planned PCI procedure after 1 mo of index
procedure
• Procedure planned to require nonstudy stents, stand-alone balloon
angioplasty, or stand-alone atherectomy
• Active bleeding at the time of inclusion
• Cardiogenic shock
• Patient with planned surgery or procedure necessitating discontin-
uation of DAPT within 1 mo after index procedure
• Patient not expected to comply with long-term SAPT
• A known hypersensitivity or contraindication to aspirin, heparin and
bivalirudin, P2Y12 inhibitors, mTOR inhibiting drugs such as
zotarolimus, biolimus A9 (or its derivatives), cobalt, nickel, platinum,
iridium, chromium, molybdenum, polymer coatings (eg, BioLinx),
stainless steel (or other metal ions found in 316 L stainless steel), zinc,
or a sensitivity to contrast media, which cannot be adequately
premedicated
• PCI during the previous 6 mo for a lesion other than the target lesion
of the index procedure
• Participation in another clinical study within 12 mo after index
procedure
• Patients with life expectancy of b2 y
bbreviations: Hgb, hemoglobin; NSAID, Nonsteroidal anti-inflammatory drug; PLT,
latelet.
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August 2019Before randomization, coronary angiography is per-
formed to evaluate coronary anatomy for suitability of
stent implantation. Patients will be followed up clinically
through 2 years, study exit, or death, whichever comes
first. A clinic visit is planned at 1 month with additional
follow-up at 2 and 6 months and 1 and 2 years after index
procedure. Follow-up data collected include angina
status, any adverse events or device deficiency data,
and prescribed antiplatelet medications.
The sponsor did not provide stents for free. The
sponsor only reimbursed investigational sites for study-
specific work not considered standard of care. Enrolled
patients received a reasonable travel fee for protocol-
required clinic visits.
Randomization and blinding
Randomization occurs before PCI by an interactive
web/voice response system. Randomized patients are
allocated 1:1 to receive either a durable polymer Resolute
Onyx or a polymer-free BioFreedom DES, stratified by
study site, diabetes, and MI status using a blocked
randomization scheme. There are currently 1,997 pa-
tients randomized in the trial.
Patients, clinical site personnel conducting patient
follow-ups, and referring/managing physicians are blinded
to randomization assignment. To minimize the risk of
patient unblinding, site staff are trained not to disclose the
implanted stent to the patient and not to mention the stent
type in the discharge letter. In addition, the sponsor's
clinical study team and the external, independent clinical
events committee (CEC) are blinded to randomization
assignment. Interventional cardiologists conducting the
procedures are not blinded to randomization.In
A
pTrial organization
The trial is approved by the appropriate ethics review
board at each clinical site. All patients will provide
written informed consent before enrollment. The trial
was designed in accordance with the Declaration of
Helsinki. The sponsor of the trial is Medtronic. All centers
selected worldwide are experienced in clinical research.
Data are collected at each clinical site and stored via
electronic case report forms.
Detailed listings of the study committees and partici-
pating sites appear in the Appendix. The role of the
Figure 2
esolute Onyx DES design. A, A single strand of composite wire is formed
to a sinusoidal design, wrapped in helical form around a mandrel, and
ser-fused at specific crowns to create its final shape. The composite wire
omprises an outer shell of cobalt alloy and an inner core of 90% platinum
nd10% iridiumalloy. B, The biocompatible BioLinx polymer system is 6 μm
ick and consists of a blend of 3 different polymers. C, ResoluteOnyxDES is
remounted on a semicompliant balloon rapid exchange delivery system.
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Volume 214steering committee is to advise study design and
execution, provide overall supervision of the study, and
have responsibility for reviewing the final study results
and determining methods of presentation and publica-
tion. The CEC will review and adjudicate all deaths and
safety end point–related adverse events (Cardiovascular
Research Foundation, New York, NY). An external,
independent data monitoring committee from Cardiovas-
cular Research Foundation will evaluate safety data and
advise the sponsor in regard to continued safety of the
study to ensure the well-being of the patients. An
independent Angiographic Core Laboratory (Beth Israel
Deaconess Medical Center, Boston, MA) will evaluate all
angiograms collected at baseline and after any MI, death,
revascularization, or stent thrombosis. Study monitors
(Medtronic MC2; Minneapolis, MN) will verify patient
data and ensure compliance with this Clinical Investiga-
tional Plan and other study requirements. The trial is
registered at www.clinicaltrials.gov (NCT03344653).
Procedure
Patients receive either Resolute Onyx or BioFreedom
stent(s) for treatment of one or more lesions in one or
more vessels. Operators are instructed to implant only the
assigned stent type during the index procedure and any
subsequent staged procedures. If the assigned study stent
cannot be placed, operators are recommended to use the
comparator device (Resolute Onyx stent or BioFreedom)
or another device at their discretion. Predilatation and
postdilatation are recommended but not mandated.
If due to clinical reasons a staged procedure is required,
it should take place within 1 month from index
procedure. Every urgent coronary reintervention before
the planned staged procedure will be considered an
event. Staged procedures in the target vessel(s) treated at
index or a segment directly adjacent to a segment treated
during the index PCI are not allowed.
If the procedure involves treating a bifurcation lesion, a
single-stent strategy (ie, a provisional stenting technique)
is recommended: stent placement in the main branch,
finalized with proximal optimization technique, followed
by placement of a second stent if inadequate results are
found in the side branch (such as threatened closure of
the side branch, dissection type B or worse, Thrombolysis
in Myocardial Infarction flow b3, or residual stenosis
N80%) (25,26).
Intravascular imaging with either ultrasound or optical
coherence tomography is allowed per local practice and
standard of care.
Resolute Onyx
The Resolute Onyx DES is manufactured using a single
strand of composite wire with a swaged shape formed
into a sinusoidal design, wrapped in helical form around a
mandrel, and laser-fused at specific crowns to create its
final shape (Figure 2) (20,21). The composite wireR
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pcomprises an outer shell of cobalt alloy and an inner core
of 90% platinum and 10% iridium alloy. The higher
density of the platinum/iridium alloy inner core improves
Figure 3
The textured abluminal surface of the BioFreedom coronary stent,
coated with the active ingredient BA9.
Table II. Primary and secondary end points
nd point
Time point(s) after index
procedure
rimary end point
Composite of cardiac death, MI, or stent
thrombosis
1 y
owered secondary end point
TLF 1 y
ther secondary end points
Composite of cardiac death, MI, and stent
thrombosis
2 and 6 mo, 2 y
Acute success: device, lesion, and procedure Index procedure
All deaths and cardiac deaths 1, 2, and 6 mo; 1 and 2 y
All MI and TVMI 1, 2, and 6 mo; 1 and 2 y
Stroke 1, 2, and 6 mo; 1 and 2 y
MACE 1, 2, and 6 mo; 1 and 2 y
TLF 2 and 6 mo, 1 and 2 y
TVF 1, 2, and 6 mo and 2 y
TLR, TVR, non-TVR 1, 2, and 6 mo; 1 and 2 y
Stent thrombosis 1, 2, and 6 mo; 1 and 2 y
Bleeding per BARC criteria 1, 2, and 6 mo; 1 and 2 y
bbreviations: BARC, Bleeding Academic Research Consortium; TVF, target vessel
ilure.
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August 2019visibility under x-ray. The strut shape was designed to
increase strut width-to-thickness ratio, which allows for a
reduced strut thickness of 81 μm without compromising
radial strength.
Zotarolimus, the drug used in Resolute Onyx DES, is a
semisynthetic rapamycin derivative with immunosup-
pressive and antiproliferative properties that arrests the
cell cycle in the G1 phase, thereby reducing cell
proliferation and neointimal hyperplasia. The biocompat-
ible BioLinx (Medtronic) polymer system is 6 μm thick
and consists of a blend of 3 different polymers
(hydrophobic C10 polymer, hydrophilic C19 polymer,
and polyvinyl pyrrolidinone). The polyvinyl pyrrolidi-
none is a hydrophilic polymer designed to increase the
biocompatibility of the stent (27). Almost 80% of the drug
is released by 30 days and completely by 180 days (27).
Resolute Onyx DES is premounted on a semicompliant
balloon rapid exchange delivery system.
BioFreedom
BioFreedom is a polymer- and carrier-free coronary
stent consisting of a 316-L stainless steel stent coated
abluminally with umirolimus, also known as biolimus A9,
or BA9 (Figure 3) and premounted on a semicompliant
rapid exchange balloon delivery system. The strut
thickness is 120 μm. BA9 is a semisynthetic sirolimus
derivative with high lipophilicity to inhibit smooth
muscle cell proliferation within the proximity of the
stent.
Antiplatelet medication
Preprocedure, a loading dose of aspirin of 250 to
500 mg is recommended in aspirin-naïve patients; oral
P2Y12 inhibitor pretreatment and loading doses are
administered according to local standard of care. During
the index procedure, heparin or bivalirudin is adminis-E
P
P
O
A
fatered per standard practice and use of GPIIb/IIIa blockers
is according to operator discretion.
After index procedure, DAPT is recommended for
1 month with a daily dose of aspirin (75-100 mg) and
P2Y12 inhibitor (75 mg clopidogrel daily as the preferred
regimen). For patients with a staged procedure within the
prespecified 1 month, DAPT is prescribed for 1 month
after the staged procedure. Patients treated with vitamin
K anticoagulants or non–vitamin K anticoagulant oral
antagonists may receive single antiplatelet therapy (SAPT)
or DAPT from the date of the index procedure onward.
Beyond 1 month, SAPT is recommended with a daily
dose of either 75 to 100 mg aspirin or 75 mg clopidogrel.
Patients who have a stent thrombosis (or another adverse
event where continued DAPT is needed) during the first
1 month may remain on DAPT beyond 1 month at the
investigator's discretion.
End points
The primary end point is the composite of cardiac
death, MI, or Academic Research Consortium (ARC)
definite/probable stent thrombosis at 1 year after index
procedure. The powered secondary end point is target
lesion failure (TLF), defined as the composite of cardiac
death, target vessel MI (TVMI), or clinically driven target
lesion revascularization (TLR) by percutaneous or surgi-
cal methods, at 1 year after index procedure. All primary
and secondary end points are listed in Table II.
Statistics
The primary end point in this trial is the composite of
cardiac death, MI, or ARC definite/probable stent
thrombosis at 1 year after index procedure. In the
LEADERS FREE Study, the observed rate of this end point
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Volume 214for the BioFreedom stent was 9.4% (12). A noninferiority
margin of 4.1% was selected for the current trial,
representing 44% of the expected rate. Therefore, the
null hypothesis is that the primary end point rate in the
treatment arm (Resolute Onyx stent) will exceed that of
the control arm (BioFreedom stent) by 4.1% or more.
Assuming the true rate for both arms in the trial is 9.4%,
with a 1-sided type I error of 0.05, an evaluable sample
size of 900 patients in each arm yields more than 90%
power. Assuming 10% loss to follow-up, a total sample
size of up to 2,000 patients will be randomized. If
noninferiority is established, a conditional test for
superiority will be subsequently performed at the 1-
sided .05 level.
If noninferiority for the primary end point is met, then
the secondary end point of TLF at 1 year will be
conditionally tested for noninferiority. The TLF rate in
LEADERS FREE was not directly reported and was
therefore estimated based on the reported components
of TLF in that trial. At 1 year, the observed rates of cardiac
death, MI and TLR with the BioFreedom stent were 4.2%,
6.1%, and 5.1%, respectively, so the TLF rate was
conservatively estimated to be 11%. A noninferiority
margin of 4.4% was selected, representing 40% of the
expected rate. Noninferiority will be achieved if the
upper limit of the 1-sided 95% CI of the difference is less
than this margin. Assuming the true rates for both arms in
the trial is 11%, with a 1-sided type I error of 0.05, an
evaluable sample size of 900 patients in each arm yields
more than 90% power. If noninferiority is established, a
test for superiority will be subsequently performed at the
1-sided .05 level.
The primary analysis will be performed according to
the intention-to-treat principle. All patients who are
randomized will be considered part of the intention-to-
treat population and will be followed up through the
primary end point at 1 year. The per-protocol population
consists of patients who received the treatment to which
they were randomized but excluding patients who do not
meet certain key inclusion criteria. The as-treated
population consists of patients who are analyzed
according to the stent type they received, rather than
their randomization assignment. The primary and pow-
ered secondary end points will also be analyzed in the
per-protocol and as-treated populations as secondary
analyses.
Categorical variables will be tested using the Fisher
exact or Cochran-Mantel-Haenszel tests as appropriate,
and continuous variables will be tested using 2-sample t
tests. Time to first event curves with Kaplan-Meier rate
estimates will be generated with calculation of hazard
ratios with 95% CIs. Subgroup analyses of the safety and
efficacy end points will be performed for the following:
acute coronary syndrome, diabetes mellitus, sex, age, and
stent/lesion characteristics including multiple vessels,
multiple lesions, and overlapping stents. The statisticalanalysis plan was written by the sponsor with input from
the steering committee. All statistical analyses will be
performed using SAS (version 9.1 or higher; SAS Institute,
Cary, NC) by the sponsor, Medtronic, and independently
validated by Baim Institute for Clinical Research (Boston,
MA).
Definitions
Death is classified as cardiac death if due to immediate
cardiac cause, including procedure-related deaths, as well
as any unwitnessed death or death of unknown cause.
Myocardial infarction is defined according to the Third
Universal Definition of Myocardial Infarction (28). Target
vessel MI is defined as MI occurring in a territory that
cannot be clearly attributed to a nontarget vessel.
Stroke is defined as sudden onset of vertigo, numbness,
dysphasia, weakness, visual field defects, dysarthria, or
other focal neurologic deficits due to vascular lesions of
the brain such as hemorrhage, embolism, thrombosis, or
rupturing aneurysm. In addition, the stroke should persist
more than 24 hours or result in death in the first
24 hours, be treated pharmacologically or nonpharma-
cologically, or have neuroradiologic diagnostic changes
suggestive of acute tissue injury.
Clinically driven TLR/target vessel revascularization
(TVR) are defined as revascularization at the target
lesion/vessel associated with a positive functional ische-
mia study or ischemic symptoms, and an angiographic
minimal lumen diameter stenosis ≥50% by quantitative
coronary angiography or revascularization of a target
lesion/vessel with diameter stenosis ≥70% by quantita-
tive coronary angiography without either angina or
positive functional study.
Target vessel failure is defined as cardiac death, TVMI,
or clinically driven target TVR. Major adverse cardiac
events include death, MI, or clinically driven TLR.
Definitions from ARC were applied for both stent
thrombosis and bleeding events (29,30). Specifically,
stent thrombosis is defined as using the ARC definite or
probable criteria, and bleeding is categorized by the
Bleeding Academic Research Consortium criteria.
Acute lesion success is defined as attainment of b30%
residual stenosis by quantitative coronary angiography
(or b20% by visual assessment) and Thrombolysis in
Myocardial Infarction flow 3 after the procedure, using
any percutaneous method. Acute device success is
defined as acute lesion success using only the assigned
device. Acute procedural success is defined as acute
lesion success without occurrence of MACE during the
hospital stay.
Study limitations
Operators are not blinded to randomization; however,
all personnel conducting follow-up will be blinded to
randomization assignments to reduce bias. The CEC is
also blinded to stent type. Results are specific to HBR
140 Kedhi et al
American Heart Journal
August 2019patients and may not be generalizable to the overall PCI
population. The power calculation is based on event rates
from a single trial, LEADERS-FREE. Therefore, although
patient inclusion/exclusion criteria are very similar
between the 2 trials, the observed event rates in
LEADERS-FREE may have been influenced by chance,
and differences in the event rates among BioFreedom-
treated patients in the current trial may impact the power
to determine non-inferiority to the Resolute Onyx DES.
Finally, the results of the present study principally apply
to patients in whom 1-month DAPT is believed to be
appropriate based on bleeding risk and does not address
the issue of optimal DAPT duration in this population.
Summary
The Onyx ONE global randomized trial is the first study
to directly compare the safety and efficacy of 2 DES
among HBR patients treated with 1 month of DAPT.
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